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A growing body of evidence supports a prodromal neurodegenerative process
preceding the clinical onset of Parkinson’s disease (PD). Studies have identified
several different prodromal markers that may have the potential to predict the
conversion from healthy to clinical PD but use considerably different approaches. We
systematically reviewed 35 longitudinal studies reporting prodromal PD features and
evaluated the methodological quality across 10 different predefined domains. We found
limitations in the following domains: PD diagnosis (57% of studies), prodromal marker
assessments (51%), temporal information on prodromal markers or PD diagnosis (34%),
generalizability of results (17%), statistical methods (accounting for at least age as
confounder; 17%), study design (14%), and sample size (9%). However, no limitations
regarding drop-out (or bias investigation), or report of inclusion/exclusion criteria or
prodromal marker associations were revealed. Lessons learned from these limitations
and additional aspects of current prodromal marker studies in PD are discussed to
provide a basis for the evaluation of findings and the improvement of future research in
prodromal PD. The observed heterogeneity of studies, limitations and analyses might be
addressed in future longitudinal studies using a, yet to be established, modular minimal
set of assessments improving comparability of findings and enabling data sharing and
combined analyses across studies.
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INTRODUCTION
Parkinson’s disease (PD) is the second most prevalent
neurodegenerative disorder. PD is characterized by motor
features of resting tremor, bradykinesia, rigidity, and postural
instability, but also non-motor symptoms (e.g., hyposmia,
depression, autonomic dysfunction) are common in PD
patients (Chaudhuri et al., 2006; Jankovic, 2008). However,
by the time motor symptoms allow a clinical diagnosis of PD
an extensive loss of dopaminergic nigrostriatal neurons will
already have taken place due to an ongoing neurodegenerative
process spanning years or even decades (Bernheimer et al.,
1973; Marek et al., 2001). Several clinical markers have been
suggested to indicate this early ‘‘prodromal’’ progressive
degenerative process preceding the clinical diagnosis of
PD (Gonera et al., 1997; Lang, 2011; Stern et al., 2012).
Such prodromal markers include motor as well as non-
motor symptoms. For instance, subtle motor signs of the
cardinal motor symptoms of PD have been shown to be more
frequent in incident PD patients than in controls (Berg et al.,
2013b). In addition, a number of non-motor symptoms such
as constipation, urinary dysfunction (Schrag et al., 2015),
FIGURE 1 | Graphical illustration of the prodromal phase with early neurodegenerative changes occurring years or even decades before the clinical
diagnosis of Parkinson’s disease (PD) can be made. Risk markers may increase the PD risk without directly being associated with neurodegenerative changes.
Only slight loss of neurons due to the normal aging process can be detected in this phase. Prodromal markers represent indicators of the early neurodegenerative
process in which neuronal loss is accelerated. This phase may ultimately lead to PD. Risk markers increase the likelihood that an individual may enter the prodromal
phase and may finally develop motor PD. Prodromal markers may indicate the ongoing neurodegenerative process and may help to identify those individuals who will
likely develop PD in the future.
olfactory dysfunction (Ross et al., 2008), depression, anxiety
(Schrag et al., 2015), and sleep disorders (Gao et al., 2011b;
Postuma et al., 2015), have been shown to occur before
the diagnosis of PD (see Figure 1 for a graphical illustration
of the concept of prodromal PD). Importantly, prodromal
markers of PD could enable an early detection of PD and
possibly more effective or even preventive early treatments of
the disease.
While numerous longitudinal cohort studies support the
concept of prodromal PD and prodromal markers (e.g., Abbott
et al., 2001; Postuma et al., 2015; Schrag et al., 2015), the
comparability of study results is hampered by methodological
differences (Lerche et al., 2015), such as design, type of
assessments and analytical methods. Furthermore, limitations
of individual studies might additionally affect comparability
and interpretation of findings. However, limitations in these
prodromal marker studies have not yet been systematically
reviewed. Therefore, we performed a systematic review of
published longitudinal studies investigating prodromal markers
in PD to examine the methodological quality of these studies
and to identify key areas that could be improved in future
research.
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MATERIALS AND METHODS
Search Criteria
This systematic review focuses on longitudinal studies in the
prodromal phase of PD. We defined prodromal markers as
indicators of an ongoing neurodegenerative process in the
central or peripheral nervous system prior to the typical
symptoms allowing a clinical diagnosis, in our case PD. In
contrast, risk factors are associated with an increased risk of
developing PD, which themselves are not a sign of an ongoing
neurodegenerative process and may never lead to it (e.g.,
pesticide exposure).
We acknowledge that the attribution of a factor to risk and/or
prodromal marker categories is sometimes difficult and disputed
(e.g., smoking habit). We therefore decided to use a pragmatic
approach based on the definitions used by the study authors
themselves, rather than impose our own definition.
We searched the literature following a two step-approach
in order to identify studies reporting prodromal marker
associations preceding the diagnosis of PD. First, we employed
a PubMed database search (November 2014) for articles
in English using the search term: ‘‘prodromal’’ and ‘‘PD’’
and ‘‘longitudinal’’. Second, we performed a MEDLINE
search (October 2015) for publications missed so far, which
identified studies using the terms ‘‘prediagnostic’’, ‘‘preclinical’’,
‘‘premotor’’ or ‘‘prodromal’’, and ‘‘Parkinson’’ (for query details
see the ‘‘Supplementary Material’’).
We disregarded markers of the ‘‘nascent sciences’’ (e.g.,
protein levels), neuro-imaging except transcranial sonography
(TCS), which can be very easily applied in neurodegenerative
disorders, or behavioral habits that could be due to personality
traits (e.g., smoking). Inclusion criteria comprised: (1) studies
providing data with the endpoint of new onset PD, i.e., the
conversion from healthy to PD, were considered; (2) assessment
of at least one prodromal symptom at the baseline investigation;
and (3) for multiple publications of the same prodromal
marker in the same cohort, the study with the largest sample
size or, if equal, the longest follow-up was selected. We
excluded: (a) study designs other than longitudinal (e.g., cross-
sectional); (b) studies focusing on risk factors; (c) studies in
which the majority of converters developed parkinsonism other
than idiopathic PD; (d) PD treatment/intervention studies;
(e) non-human studies; and (f) review articles, book chapters,
editorials, commentaries, hypothesis articles, meta-analyses, and
abstracts.
The initial PubMed search listed 292 publications. Of
these, 251 were excluded after screening of abstracts for the
exclusion criteria above. Here, often multiple reasons for
exclusion applied (e.g., molecular marker, cross-sectional,
non-human) and we therefore resigned from describing the
individual reasons for exclusion of the respective studies in
detail. After full text screening of 41 articles, 14 additional
publications were excluded while 28 articles were found
to be eligible for inclusion in the review. The MEDLINE
search listed 1144 publications and after abstract screening
seven additional articles were identified that had been
missed in the initial PubMed search. Full text screening
of these seven articles did not lead to further exclusions.
In total, 35 eligible publications of longitudinal studies
investigating prodromal markers in PD were included and
systematically reviewed for limitations. However, the evaluation
of specific prodromal marker associations or their comparison
between studies was not in the scope of this systematic
review.
Limitations of Studies
A specific set of criteria or limitations to be considered for
the evaluation of longitudinal studies in prodromal PD has
not been established. Yet, for the interpretation of reported
prodromal marker associations, numerous and partly marker
specific aspects may have to be considered. As a starting
point, we used evidence-level criteria (Edlund et al., 2004;
Maetzler et al., 2009; originally designed by the American
Academy of Neurology (AAN) for intervention study evaluation)
comprising five more generic aspects. We complemented
this list of limitation categories by methodological and
informative aspects more specific to longitudinal studies in
prodromal PD. In total, 10 different limitation categories were
defined:
(1) Study design: we regarded prospective cohort studies,
historical cohort and ‘‘nested’’ case-control studies as the most
valid study designs, where participants belonged to an explicit
cohort and prodromal marker data had been already collected
prior to disease onset. Conventional case-control studies or
other designs were regarded as methodologically weaker and
therefore fulfilled the criterion for this limitation. We also
indicated whether studies were population-based or clinical
cohorts, but we did not include this aspect in the evaluation of
limitations.
(2) No clearly stated inclusion or exclusion criteria; (3) no
adequate accounting for drop-outs (or investigation of potential
drop-out bias) in studies with less than 80% of enrolled
subjects at follow-up; (4) insufficient number of participants
(for prospective cohort studies, historical cohort and ‘‘nested’’
case-control studies: n < 50 at baseline, for retrospective and
conventional case-control studies: n < 100); (5) no presentation
of effects indicated by odds ratio (OR), relative risk (RR),
hazard ratio (HR), likelihood ratio (LR), sensitivity/specificity,
or lack of clear descriptive results from which such effects could
be calculated. Mere t-test results or reported P-values were
considered insufficient.
We considered five additional limitation criteria, which are
specifically relevant for the evaluation of reported prodromal
marker associations; (6) diagnosis of idiopathic PD by non-
specialists in movement disorders, only probable PD diagnosis
or uncertainties regarding the parkinsonian disease status in
‘‘healthy’’ individuals at baseline; (7) limitations in prodromal
marker assessments (e.g., self-reports, marker diagnosis by non-
specialists); (8) reduced generalizability of findings (e.g., only
males); (9) limitations of statistical analyses, e.g., no appropriate
accounting for confounders (at least: age) in the design or
analysis; and (10) absent or limited data on the temporal
sequence, e.g., duration of marker presence at baseline, or latency
period between exposure measurement and onset of PD.
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RESULTS
Descriptive Results
The 35 reviewed studies assessed the following prodromal
markers: five studies investigated sleep disturbances (three Rapid
eye movement sleep Behavior Disorder (RBD) (Schenck et al.,
1996; Iranzo et al., 2014; Postuma et al., 2015), two daytime
sleep (Abbott et al., 2005; Gao et al., 2011b)), three hyposmia
(Haehner et al., 2007; Ross et al., 2008; Ponsen et al., 2010),
three constipation (Abbott et al., 2001; Savica et al., 2009;
Gao et al., 2011a), three cardiac function (i.e., cardiac stress
test performance (Palma et al., 2013; Yahalom et al., 2014)),
cardiac disease (Jain et al., 2012), one cognitive deficits (Sánchez-
Ferro et al., 2013), one pain (Lin et al., 2013), one vital
exhaustion (Clark et al., 2013), 10 anxiety/depression (three
anxiety (Weisskopf et al., 2003; Bower et al., 2010; Lin et al.,
2015), five depression (Leentjens et al., 2003; Fang et al., 2010;
Shen et al., 2013; Gustafsson et al., 2015; Walter et al., 2015), two
anxiety/depression (Ishihara-Paul et al., 2008; Jacob et al., 2010)),
one erectile dysfunction (Gao et al., 2007), one transcranial
sonography substantia nigra hyperechogenicity (TCS SN+; Berg
et al., 2013a), and six studies (Gonera et al., 1997; Gaenslen et al.,
2011; Berg et al., 2013b; Lerche et al., 2014; Plouvier et al., 2014;
Schrag et al., 2015) assessed several prodromalmarkers ormarker
combinations without a primary focus on a particular prodromal
marker.
Of the 35 studies, 28 (80%) comprised population-based
samples or medical register data and 7 (20%) clinical cohorts.
Study details including study design, markers, sample size,
temporal information, prodromal marker effects, and limitations
are given in the Supplementary material.
Limitations in Studies on Prodromal
Markers in PD
Study Design
Five (14%) studies showed limitations in study design (two
retrospective studies (Shen et al., 2013; Lin et al., 2015) and
three conventional case-control studies (Gonera et al., 1997;
Jacob et al., 2010; Gaenslen et al., 2011)). The other studies were
prospective cohort studies (n = 22; 63%; Schenck et al., 1996;
Abbott et al., 2001, 2005; Weisskopf et al., 2003; Gao et al., 2007,
2011a,b; Haehner et al., 2007; Ishihara-Paul et al., 2008; Ross
et al., 2008; Bower et al., 2010; Ponsen et al., 2010; Jain et al., 2012;
Berg et al., 2013a,b; Clark et al., 2013; Lin et al., 2013; Sánchez-
Ferro et al., 2013; Iranzo et al., 2014; Lerche et al., 2014; Postuma
et al., 2015; Walter et al., 2015), or nested case-control studies
(n = 8; 23%; Leentjens et al., 2003; Savica et al., 2009; Fang et al.,
2010; Palma et al., 2013; Plouvier et al., 2014; Yahalom et al., 2014;
Gustafsson et al., 2015; Schrag et al., 2015).
No Inclusion/Exclusion Criteria
No study showed a total lack of inclusion or exclusion criteria.
However, criteria differed between studies dependent on the
data source (e.g., insurance/medical registers, hospital records,
clinical study) and on study-specific inclusion/exclusion criteria
as relevant for marker assessments and PD diagnosis.
Drop-Outs
No study reported a drop-out rate of over 20% between
baseline and last follow-up without investigating factors
associated with the drop-out to exclude a potential
drop-out bias.
Insufficient Sample Size
Three studies (9%) did not fulfill the criterion of sufficient sample
size. Two prospective cohorts (Schenck et al., 1996; Haehner
et al., 2007) with <50, and one case-control study (Gonera et al.,
1997) with<100 participants at baseline.
No Report of Marker Associations
No study failed to report statistical effects or detailed descriptive
statistics.
Reduced Validity of PD Diagnosis
Eighteen studies (51%; Gonera et al., 1997; Leentjens et al.,
2003; Weisskopf et al., 2003; Gao et al., 2007, 2011a; Ishihara-
Paul et al., 2008; Ross et al., 2008; Savica et al., 2009;
Bower et al., 2010; Fang et al., 2010; Jacob et al., 2010;
Jain et al., 2012; Clark et al., 2013; Lin et al., 2013, 2015;
Sánchez-Ferro et al., 2013; Gustafsson et al., 2015; Schrag
et al., 2015) showed diagnostic limitations, as the diagnosis
was not explicitly made by a movement disorder specialist.
Alternatively, PD diagnosis was based on disease classification
codes, self-reports, use of PD medication (e.g., levodopa) and/or
insurance/medical registers, or death certificate documentation.
Two additional studies (6%; Haehner et al., 2007; Walter
et al., 2015) included ‘‘healthy’’ individuals with borderline
PD motor symptoms as indicated by Unified PD Rating Scale
part III (UPDRS-III) scores. Here, a UPDRS-III borderline
score was defined as 5 or more (Haehner et al., 2007),
or individuals with UPDRS-III > 9 (but without definite
PD diagnosis) were also considered ‘‘healthy’’ (Walter et al.,
2015).
Limitations in Prodromal Marker Assessments
Eighteen studies (51%; Gonera et al., 1997; Abbott et al.,
2001, 2005; Leentjens et al., 2003; Weisskopf et al., 2003;
Gao et al., 2007, 2011a,b; Ishihara-Paul et al., 2008; Bower
et al., 2010; Fang et al., 2010; Jacob et al., 2010; Gaenslen
et al., 2011; Lin et al., 2013, 2015; Lerche et al., 2014;
Gustafsson et al., 2015; Schrag et al., 2015) showed limitations
in prodromal marker assessments. Marker information was
based on questionnaires/self-reports in 13 studies with 2 studies
(Gao et al., 2007; Gaenslen et al., 2011) using longer term
retrospective self-reports with possible recall bias, and was based
on medical records (e.g., diagnosis of depression in primary
care) in five studies (Gonera et al., 1997; Leentjens et al.,
2003; Fang et al., 2010; Gustafsson et al., 2015; Schrag et al.,
2015).
Reduced Generalizability of Findings
Findings of six studies (17%; Schenck et al., 1996; Abbott et al.,
2001, 2005; Weisskopf et al., 2003; Gao et al., 2007; Ross et al.,
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FIGURE 2 | Frequency of limitations in prodromal PD studies.
2008) might not be generalizable to females as only males were
investigated.
Limitations of Statistical Analyses
Six studies (17%; Schenck et al., 1996; Haehner et al., 2007;
Berg et al., 2013a,b; Lerche et al., 2014; Walter et al., 2015)
did not account for potentially confounding age effects in
their statistical analysis or design. Many studies additionally
accounted for a number of other confounders as relevant for PD,
elderly individuals and/or prodromal marker interpretation in
the statistical analysis or via appropriate exclusion criteria.
FIGURE 3 | Frequencies (in %) of studies with a limitation in the 10 predefined limitation categories. Frequencies are shown for studies with, in total,
1 limitation, 2 limitations and studies with 3 or more limitations.
Temporal Uncertainties
Twelve studies (34%; Gao et al., 2007, 2011a,b; Haehner et al.,
2007; Ishihara-Paul et al., 2008; Jain et al., 2012; Berg et al.,
2013a,b; Sánchez-Ferro et al., 2013; Shen et al., 2013; Lerche
et al., 2014; Plouvier et al., 2014) did not report any temporal
information on the duration of marker presence at baseline,
PD conversion (relative to baseline), or PD incidence (in
person-years) in presence/absence of prodromal markers, in
addition to the mere time-span between baseline and last
follow-up.
Overall, five studies (14%; Ponsen et al., 2010; Palma et al.,
2013; Iranzo et al., 2014; Yahalom et al., 2014; Postuma et al.,
2015) showed no limitation according to our criteria. However,
most studies (n = 30, 86%) showed one or more limitations
out of the 10 proposed categories. Limitations in two categories
per study [median; mean (SD): 1.7 (1.1) limitations] were most
frequently found. Figure 2 shows how many of the reviewed
studies had 0, 1, 2, 3 or 4 limitations in the 10 proposed limitation
categories.
For studies with 1, 2 and those with 3 or more limitations,
the frequency [%] of studies with limitations is shown for each
of the predefined limitation categories (Figure 3). Only studies
with ≥3 limitations showed limitations in sample size and,
compared to studies with fewer limitations, more frequently
showed limitations in all other categories (if at all observed
for that category). However, marked differences were only
observed for limitations in study design, which were more
than twice as frequent in studies with ≥3 limitations (30%)
compared to studies with 2 limitations (12%). Studies with 1
limitation only showed limitations in PD diagnosis or temporal
information.
Frontiers in Aging Neuroscience | www.frontiersin.org 5 June 2016 | Volume 8 | Article 147
Heinzel et al. Limitations in Prodromal PD Research
DISCUSSION—LESSONS LEARNED
In this systematic review we set out to identify and categorize
limitations of longitudinal studies that were designed to examine
potential prodromal features of PD. We aimed to set the
frame for a critical evaluation of prodromal markers in PD
considering limitations as well as individual strengths of studies
and to provide recommendations for the improvement of
ongoing and future longitudinal studies. We acknowledge the
great efforts in each of the reviewed longitudinal studies, which
were designed when little was known about prodromal PD.
We defined 10 limitation categories for prodromal
longitudinal studies based on evidence-level-criteria (Edlund
et al., 2004; Maetzler et al., 2009) as well as additional aspects
important for the evaluation of prodromal marker associations.
While five studies (14%) showed no limitation in the proposed
categories, 30 studies (86%) showed 1 or more limitations
suggesting that future studies and reporting of findings can be
improved.
Importantly, limitations can introduce different types of bias
(e.g., non-differential or differential) which can either attenuate
or enhance associations so that the observed associations may
be either an under- or over-estimate of the ‘‘true’’ effects. The
different limitation categories are discussed below.
Study Design (14% of Studies)
Two retrospective cohort and three conventional case-control
studies were considered methodologically weaker compared
to prospective or nested case-control studies. These designs
may be more susceptible to bias in data selection/analysis,
and confounders may be more likely to go unrecognized.
Thereby, associations rather than true causal relationships
between prodromal markers and the development of PD might
be established.
No Inclusion/Exclusion Criteria (0%)
Specifications of inclusion/exclusion criteria varied between
studies. While their appropriateness was not assessed, studies
should carefully select specific and appropriate criteria to
increase the specificity of prodromal marker effects (without
introducing a selection bias).
Drop-Outs (0%)
Apart from the reduction of sample size, drop-out of participants
over time might not be random but associated with other
characteristics, e.g., age, sex, or health-related aspects, such as
depression or physical mobility. Thus, demographics and factors
related to markers or PD diagnosis should be investigated,
especially when the drop-out rate is high, e.g., >20%. However,
also a small number of (highly biased) drop-outs may alter
findings, and potential biases in drop-outs should therefore
always be explored. However, drop-out rates cannot always
be inferred from the data and factors linked to drop-out (or
motivational aspects of study participation over years) with
potential impact on prodromal marker associations remain
elusive and should be further investigated.
Insufficient Sample Size (9%)
The criterion of required sample size was relatively liberal and
was based on intervention study criteria (Edlund et al., 2004).
The lack of specificity of some prodromal markers and/or
potential confounders may necessitate a larger sample size to
obtain valid and reliable evidence of specific prodromal marker
effects. For rare markers (e.g., RBD) with putatively strong
associations, smaller sample sizes might suffice than for rather
common/unspecific markers with smaller associations. The lack
of statistical power due to a small sample size might result
in false-negative prodromal marker findings (type II error).
However, medical register studies in particular by far exceeded
the required sample size.
No Report of Marker Associations (0%)
Results should provide statistical effects as ORs, RRs, HRs, LRs
or sensitivity/specificity, or at least provide detailed descriptive
statistics (of prodromal markers both in PD converters and
non-converters). In addition to considering limitations, detailed
report of associations is important for comparability of findings
and for meta-analyses, which should be maintained as none of
the reviewed studies showed limitations in this aspect.
Reduced Validity of PD Diagnosis (57%)
PD diagnosis by professionals other than movement disorder
specialists or surrogate measures for clinical PD diagnosis (e.g.,
antiparkinsonian medication) is prone to misdiagnosis (Tolosa
et al., 2006). Thereby, the specificity of PD prodromal marker
findings might have been reduced due to uncertainties in
PD diagnosis in 18 of the reviewed studies (51%). However,
many studies of these studies put effort into cross-validation of
diagnoses in a sub-sample and/or applied multiple criteria (e.g.,
repeated PD diagnosis in medical records and PD medication
intake) to reduce false-positive PD diagnoses. In two studies
(6%) individuals with borderline UPDRS-III scores at baseline
were included as healthy subjects, thus, a rather late prodromal
phase might have been investigated. Most studies did not report
baseline UPDRS-III scores (see below: ‘‘Temporal Uncertainties’’
Section), which should be considered in future publications.
Limitations in Prodromal Marker Assessments (51%)
Prodromal markers were frequently assessed using self-
reports, interviews, questionnaires or medical record data (with
unknown validity of entry or diagnosis, i.e., general practice
instead of specialist marker diagnosis). Due to practical aspects
quantitative/objective assessments can be difficult to realize
for some prodromal markers, in particular, in studies with a
large sample size. The degree to which reliability of prodromal
markers and evidence of findings is limited may differ between
studies and assessment methods. Self-report questionnaires
and interviews are prone to retrospective recall bias, deliberate
false statements (e.g., erectile dysfunction, depression), or
unawareness of marker presence (e.g., hyposmia). Also,
subjective marker information may be erroneous due to stress,
memory deficits, depression or investigator effects. However,
also quantitative/objective information may be erroneous (e.g.,
diagnosis of depression by general practitioner, olfactory testing
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when having a cold). Potentially, register data carry the risk of
over-diagnosis or less reliable assessment of markers/diseases
due to non-specialist diagnosis or insurance/financial reasons
affecting data entries. For some markers objective marker
information is rarely available (e.g., diagnosis of constipation
by gastroenterologist instead of self-reports), and the degree
of agreement between quantitative/objective and subjective
assessments may vary. For each study and prodromal marker
these issues need to be considered. Importantly, in prospective
studies a possible bias or marker assessment error likely does
not differ between PD converters and non-converters rendering
these errors less critical for prodromal marker associations.
Reduced Generalizability of Findings (17%)
Studies with reduced generalizability investigated only male
cohorts. Some markers are for obvious reasons restricted to
a subgroup of individuals (e.g., erectile dysfunction in males).
However, other prodromal markers studied in males only would
require confirmation in samples containing females.
While not considered for this limitation criterion, for
some clinical cohorts and cohorts selectively enriched through
recruitment of individuals with prodromal markers, or in
at-risk groups (e.g., RBD or genetic risk groups), the relevance
and generalizability of findings may need further validation
in population-based cohorts. However, even some of the
population-based samples are not fully random and specific
interactions or biases may need to be considered for these
samples.
Limitations of Statistical Analyses (17%)
Prodromal marker associations might be modulated by
confounders, and for each prodromal marker a different set
of confounders might play a role. Advanced age is the most
important risk factor for PD and many prodromal markers are
more frequent with increasing age. Therefore, statistical analyses
or study design should at least account for age as a confounder to
increase the specificity of prodromal marker associations. Some
studies additionally accounted for a number of other relevant
confounders in the statistical analysis (or via appropriate
exclusion criteria or matching) that might have increased the
specificity of reported prodromal marker associations.
Temporal Uncertainties (34%)
For the characterization and evaluation of prodromal marker
associations with the conversion from healthy to PD, temporal
information is crucial to understand the temporal sequence of
progressive neurodegeneration preceding PD diagnosis. This
neurodegenerative process and the corresponding association
with a prodromal marker may span a (much) longer time than
the time span from baseline to PD diagnosis. However, marker
duration at baseline is rarely reported and thus it remains
elusive to what extent marker duration rather than marker
presence influences conversion to PD. All available (temporal)
information of prodromal markers and PD diagnosis, as well
as motor symptom severity (at each visit) should be reported
to advance the understanding of temporal aspects of prodromal
motor symptom progression and prodromal markers in PD.
Some limitations are unavoidable, and yet studies with
limitations have yielded important information, which might
otherwise have been missed. For instance, longitudinal
studies with extensive assessment batteries as well as large
sample sizes need to use easy-to-apply and quick-to-perform
assessments such as questionnaires. Nevertheless, findings from
these studies contributed with valuable findings despite the lack
of quantitative/objective assessments.
Still, for a correct interpretation of prodromalmarker findings
and the reported effect sizes, potential limitations should be
considered to improve comparability of findings and designs,
assessments and analyses of ongoing and future studies in
prodromal PD. In this systematic review, the three most frequent
limitations were in marker assessments, report/availability of
temporal information, and PD diagnosis. These limitations are
important to address and in this way may improve future studies
of prodromal PD.
In addition to the limitation categories investigated, the
review of longitudinal studies in prodromal PD revealed other
important aspects to be considered in future research.
Table 1 lists important issues to be addressed in future studies
on prodromal markers in PD.
Further Suggestions and Lessons Learned
1. In PD and/or its prodromal phase, markers may not always
be present or deteriorate linearly. The key advantage of
longitudinal studies is the ability to show the trends in a
marker over time, but reversion or fluctuation of marker
status over time and its relevance for conversion to clinical
PD has not been reported in any of the studies. For
continuous markers (e.g., marker severity) and dichotomous
markers (present/absent), the longitudinal (possibly non-
linear) changes or reversion rate until PD diagnosis may,
however, be highly valuable for PD prediction models and
future therapeutic strategies in the prodromal phase. From
this perspective, it will be of relevance to distinguish between
dynamically changing state markers, and stable trait markers
(possibly RBD, TCS SN+).
2. Some patients with an initial diagnosis of PD will show
additional and/or atypical symptoms that require a
re-evaluation of the initial diagnosis. Thus, individuals
converting to PD should be clinically investigated over an
TABLE 1 | Open research questions in prodromal Parkinson’s
disease (PD).
• What is the temporal sequence of occurrence of prodromal markers and
what are characteristic changes in severity/frequency of specific prodromal
markers over time?
• How are prodromal markers related to another and to possible confounders
(e.g., age, sex)?
• How are differences in prodromal markers between individuals and marker
constellations related to the PD risk?
• To what extent are prodromal marker effects generalizable to the general
population?
• Is the heterogeneity in (idiopathic) PD symptoms/subtypes already
indicated by prodromal markers?
• Can risk/prodromal markers be used for calculations of valid and reliable
PD risk probabilities?
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extended period of time to substantiate the PD diagnosis and
to gain further information on subgroups of PD patients and
their optimal treatment.
3. Non-significant findings of prodromal markers, sub-group
analyses or findings of interactions (with other prodromal
markers) have not always been reported, although this
information would be valuable especially in a future meta-
analysis.
4. Enriched cohorts, i.e., individuals with a relatively increased
risk of developing PD due to stratification by prodromal/risk
factors (male gender, TCS SN+, positive dopamine
transporter scintigraphy, PD relatives), may have a higher PD
conversion rate, thus providing greater statistical power for
a given sample size or shorter study duration. However, it
needs to be considered that for single prodromal marker
associations other confounders, e.g., additional risk or
prodromal markers, might play a role.
5. It is widely acknowledged that PD is a heterogeneous disease
(Foltynie et al., 2002; Erro et al., 2013) and symptom (or
sub-symptom) severity, progression rate, as well as many
other factors may vary among individual PD patients. This
complexity has so far not been addressed by prodromal PD
marker studies with a single endpoint of (idiopathic) PD.
Recommendations for Future Prodromal
PD Marker Research
In addition to the present findings and lessons learned from
longitudinal studies in the prodromal phase of PD, a large
degree of heterogeneity in studies both in the prodromal and
clinical phase of PD has been reported (Lerche et al., 2015). This
heterogeneity concerns the markers assessed (or not assessed),
the assessment tools used, and study design (e.g., age at inclusion,
frequency of follow-up), thereby reducing comparability of study
findings. Based on this experience, we propose a practical
approach to advance prodromal PD marker research.
Modular Minimal Set of Assessments
for Longitudinal Studies in (Prodromal) PD
Ongoing as well as new longitudinal studies may benefit from
using a common dataset that is shared with other studies.
This formal core dataset should be included in all studies (e.g.,
demographic data) and can be extended by specific additional
modules meeting study resources and needs to answer specific
scientific hypotheses. While such a modular minimal set of
assessments has not yet been established, two major advantages
support this concept. First, when studies are comparable in data
quality, replication studies as well as testing of new hypotheses
using existing data of published studies promise to be more
successful. As each study would still have additional and unique
characteristics and sample composition a modular minimal set
of assessments would advance our understanding of prodromal
PD by improving quality of studies and publications. Second,
data sharing for joint analysis would be greatly facilitated by a
common data approach. In the future, the proposed cooperative
endeavor may provide more valid and reliable prodromal
markers (or marker profiles) than single and largely unique
studies, and may thereby allow to more accurately investigate the
multi-factorial prodromal neurodegenerative process ultimately
leading to PD.
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